Clinical Trial Detail

NCT ID NCT03441100
Title TCR-engineered T Cells in NSCLC and HCC Patients
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Immatics US, Inc.
Indications

hepatocellular carcinoma

lung squamous cell carcinoma

Therapies

Cyclophosphamide + Fludarabine

Aldesleukin

IMA202

Age Groups: adult senior

No variant requirements are available.